Lexicon Pharmaceuticals, Inc. Named One of the Best Places to Work by The Scientist
THE WOODLANDS, Texas, May 15 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. today announced that it has been named by The Scientist as one of the "Best Places To Work in Industry."
"This is the fourth year running in which The Scientist has named our firm one of the Best Places to Work in Industry," said Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer. "The talent and dedication of our employees is the cornerstone of Lexicon's success and we strive daily to make Lexicon a positive, innovative, supportive place to work. We salute our employees' passion for science and our mission of bringing breakthrough treatments to market."
The Scientist, a life sciences industry magazine, received responses to its 5th annual survey from 248 life sciences companies worldwide. Respondents were asked to assess their working environment according to 45 criteria in categories including internal communications, quality of the research environment and opportunities for training and development. Based on these survey responses, The Scientist compiled a list of the top 15 large and small companies in which to work. The Scientist's May issue, available in print and online, features detailed survey results and rankings.
Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc., N.V. Organon and Takeda Pharmaceutical Company Limited. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.
CONTACT: Bobbie Faulkner, Manager, Investor Relations of Lexicon,+1-281-863-3503, email@example.com
Web site: http://www.lexpharma.com/